TriangleiExosomes in Treating Participants… (NCT03608631)
iExosomes in Treating Participants With M… trial for Metastatic Pancreatic Adenocarcinoma (NCT03608631). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Pancreatic cancer is usually found late, and nine in ten tumors run on one mutant gene, KRAS. For its commonest form, G12D, treatments are only now emerging.
The idea: instead of a drug, send instructions to switch the gene off.
Cells trade tiny packets called exosomes. In the lab, exosomes from donor stem cells are loaded with a short piece of RNA built to silence KRAS G12D. Infused into a vein, a surface tag tells the body's cleanup cells to leave them alone, and they collect in tumors. In mice, they slowed pancreatic tumors and lengthened survival.
This trial, at MD Anderson with Brandon Smaglo, gives them to people whose cancer carries G12D and has spread. First question: safety. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.